Clinical Trials Browser

Withdrawn × OTHER × Magnetic Resonance Spectroscopy × Clear all

NCT07082270 2026-04-15

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Carcinoma, Transitional Cell

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05904704 2025-11-14

Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors

Phase NA Withdrawn

Brain Neoplasms

NCT05720624 2025-10-22

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

Phase 1 Withdrawn

Central Nervous System Neoplasms

NCT04910425 2025-10-21

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT05483023 2025-10-14

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Phase 2 Withdrawn

Endometrial Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT06670976 2025-08-26

Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma

Phase 1 Withdrawn

Sarcoma

NCT05717140 2025-08-07

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Phase 1 Withdrawn

Melanoma

NCT05840770 2025-05-26

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06572631 2025-05-25

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Phase 1 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05600556 2025-05-15

Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT)

Phase NA Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT03581500 2025-04-23

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT06206876 2025-01-17

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT05653661 2025-01-07

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Withdrawn

Neoplasm Metastasis

NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04580836 2024-10-26

MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial

Phase 2 Withdrawn

Carcinoma, Renal Cell

NCT06427369 2024-09-27

An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04023240 2024-08-12

68-Ga-FAPI PET Imaging in Malignancy

Phase 2 Withdrawn

Neoplasms

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Phase 1/2 Withdrawn

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma

NCT06137651 2024-04-01

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

Phase 1 Withdrawn

Brain Neoplasms, Breast Neoplasms, Meningeal Carcinomatosis

NCT04140513 2024-03-08

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

Phase NA Withdrawn

Carcinoma, Oropharyngeal Neoplasms

NCT05034562 2024-03-07

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT05111314 2023-11-07

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

Phase EARLY_PHASE1 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT05728372 2023-10-10

64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation

Phase EARLY_PHASE1 Withdrawn

Neoplasm Metastasis

NCT05935774 2023-08-25

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05677373 2023-08-18

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Phase 1/2 Withdrawn

Uveal Melanoma

NCT04483414 2023-05-19

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT04605614 2022-06-09

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Phase 1 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT03234309 2021-11-10

Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors

Phase 2 Withdrawn

Brain Neoplasms

NCT02857218 2021-09-16

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer

Phase EARLY_PHASE1 Withdrawn

Gastrointestinal

Esophageal Neoplasms

NCT02919332 2020-07-24

Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

Glioblastoma, Glioma

NCT03506802 2020-07-24

NYSCT MM

Phase 1 Withdrawn

Multiple Myeloma

NCT03613259 2020-06-09

Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma

Phase EARLY_PHASE1 Withdrawn

Sarcoma

NCT03065712 2020-05-12

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

Phase 2 Withdrawn

Breast Neoplasms

NCT03611205 2019-08-07

Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy

Phase NA Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT00645385 2019-06-04

Gliadel-MRS

Astrocytoma, Glioblastoma, Neoplasms, Oligodendroglioma

NCT00963300 2018-11-26

MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy

Phase NA Withdrawn

Prostatic Neoplasms

NCT01789892 2018-06-28

Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer

Phase NA Withdrawn

Lung Neoplasms

NCT02872519 2018-06-06

PET Imaging of Ovarian Carcinoma With 18F-FSPG

Phase EARLY_PHASE1 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01788280 2018-02-07

Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Phase 2 Withdrawn

Glioblastoma

NCT02590497 2018-01-31

Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery

Phase NA Withdrawn

Glioblastoma

NCT03013387 2017-08-25

Dosimetry Guided PRRT With 90Y-DOTATOC

Phase 2 Withdrawn

Medulloblastoma, Meningioma, Neuroblastoma

NCT02194452 2017-04-28

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

Phase NA Withdrawn

Familial ependymoma, Astrocytoma, Brain Neoplasms, Craniopharyngioma, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroma, Acoustic, Oligodendroglioma, Pinealoma, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Glioma, Subependymal, Gliosarcoma, Optic Nerve Glioma

NCT00471835 2017-01-19

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01961934 2016-09-28

C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression

Phase 2/3 Withdrawn

Glioblastoma, Glioma, Recurrence

NCT02169063 2016-08-31

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

Phase NA Withdrawn

Prostatic Neoplasms